Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.12761 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Miroslav Vujasinovic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Pancreatic Diseases, Fatty Liver, Pancreatitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Crohnâ€s and Colitis Organisation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Ruth och Richard Julins Stiftelse.
Abstract (Originalsprache)
Introduction
Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been linked to pancreatic diseases, but evidence from population‐based studies with liver histology is lacking. Aims and methods In this population‐based cohort including all Swedish adults ( n = 8563) with biopsy‐proven MASLD, we aimed to investigate incidences of pancreatic diseases compared with matched reference individuals from the general population ( n = 38,858) and full siblings ( n = 6696). Using Cox proportional hazard models, we calculated multivariable adjusted hazard ratios (aHRs) and confidence intervals (CIs).
Results
We documented 359 incidents of pancreatic diseases in MASLD patients and 880 events in matched reference individuals, resulting in an incidence rate difference of 1.54 (95% CI, 1.25–1.84). The relative risk of pancreatic disease was highest in the first two years after MASLD diagnosis (aHR, 2.19 [95% CI, 1.92–2.50), but remained statistically significant increased even up to ten years [aHR, 1.60 (95% CI, 1.38–1.85)]. The most common pancreatic disease in individuals with MASLD was acute non‐biliary pancreatitis (1.44 vs. 0.44 events/1000 PY), followed by chronic pancreatitis (0.54 vs. 0.12/1000 PY) and pancreatic cancer (0.88 vs. 0.47/1000 PY). We documented 130 versus 344 pancreas‐related deaths among individuals with MASLD and their matched comparators, yielding an absolute risk difference of 0.51/1000 PY and an aHR of 2.41 (95%CI = 1.95−2.97). The findings were consistent in sibling‐controlled analyses with an aHR of 2.21 (95%CI = 1.69–2.90).
Conclusions
MASLD was associated with significantly higher rates of acute and chronic pancreatitis of predominantly non‐biliary origin, as well as an increased risk of pancreatic cancer and pancreas‐related mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Gastroenterology and Hepatology, University Digestive Health Care Center Basel-Clarunis, Basel, Switzerland.
- Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Unit of Upper Gastrointestinal Surgery, Saint Göran's Hospital, Stockholm, Sweden.
ORCID-Profile: Miroslav Vujasinovic, David Bergman, J-Matthias Löhr
Förderung
- European Crohnâ€s and Colitis Organisation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Ruth och Richard Julins Stiftelse
- Mag-TarmFonden, Swedish Gastroenterology Society
Zitieren
APA
Vujasinovic, M., Ebrahimi, F., Roelstraete, B., Bergman, D., Sun, J., Sadr-Azodi, O., Löhr, J. M., & Ludvigsson, J. F. (2025). Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12761
Vancouver
Vujasinovic M, Ebrahimi F, Roelstraete B, Bergman D, Sun J, Sadr-Azodi O, et al. Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12761
BibTeX
@article{Vujasinovic2025,
author = {Vujasinovic, Miroslav and Ebrahimi, Fahim and Roelstraete, Bjorn and Bergman, David and Sun, Jiangwei and Sadr-Azodi, Omid and Löhr, J-Matthias and Ludvigsson, Jonas F},
title = {Metabolic Dysfunction‐Associated Steatotic Liver Disease and Pancreatic Disease—A Population‐Based Nationwide Cohort and Sibling‐Controlled Study},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.12761}
}
EUVIMED